FIELD: medicine.
SUBSTANCE: group of inventions relates to neurology and concerns using a therapeutically effective amount of a composition for preparing a medicament for stimulating remyelination of neurons in a mammal, wherein said neurons are demyelinated by cell respiration disorders. Composition contains a.) water of pharmaceutical category; b.) at least one processing amplifier selected from a group of materials consisting of sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium triphosphate, sodium diphosphate, sodium monophosphate and potassium phosphates; and c.) gold nanocrystals, suspended in said water to form a suspension. Said nanocrystals: i.) have surfaces which include at least one characteristic selected from a group of characteristics consisting of: (1) organic chemical components are not attached to or do not stick to said surfaces, and/or (2) they have a clean surface and have no chemical components attached or adhered to surfaces other than water or said processing amplifier, which change operation of said nanocrystals; ii.) have a particle size modulus of less than 50 nm; iii.) are present in said suspension in concentration of 2–3000 ppm; and d.) said suspension has pH of 5 to 9.5 and a zeta potential of at least -30 mV. Also presented is using a therapeutically effective amount of the nanosuspension for preparing a medicinal agent for treating a disease in a mammal, including neuron demyelination caused by cellular respiration disorder in said neurons, wherein said drug stimulates remyelination of said neurons.
EFFECT: group of inventions provides stimulating neuronal remyelination in a mammal, wherein said neurons are demyelinated by cell respiration disorder, wherein the composition contains elementary gold nanosuspension.
12 cl, 51 dwg, 5 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF DEMYELINATING DISEASES | 2019 |
|
RU2805061C2 |
ANIMAL MODEL EXPRESSING LUCIFERASE UNDER CONTROL OF THE MYELIN BASIC PROTEIN PROMOTER (MBP-LUCI) AND USE OF THE MODEL FOR BIOLUMINESCENCE IN VIVO IMAGING | 2010 |
|
RU2601128C2 |
ACTIVE DRUG INGREDIENT, DRUG, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF DEMYELINATING DISEASES OF LIVING ORGANISM, INCLUDING DISEASE PREVENTION | 2015 |
|
RU2631887C2 |
NEW METHODS FOR TREATING MULTIPLE SCLEROSIS | 2018 |
|
RU2765820C2 |
DRUG COMBINATION FOR TREATING MULTIPLE SCLEROSIS | 2024 |
|
RU2828047C1 |
COMPOSITION AND METHOD OF AUTOIMMUNE DISEASES TREATMENT | 2012 |
|
RU2621129C2 |
GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
TEST MODEL FOR INVESTIGATING ACTION OF DRUGS WHICH PREVENT DEMYELINATION, METHOD FOR PREPARING AND USING THEREOF | 2019 |
|
RU2736070C1 |
METHOD OF PROVIDING REQUIRED LEVELS OF GLIAL GROWTH FACTOR 2 IN PLASMA | 2009 |
|
RU2530650C2 |
METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS | 2014 |
|
RU2687097C2 |
Authors
Dates
2019-04-30—Published
2014-05-08—Filed